Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers - Drug Trials For Money - Paid Clinical Trials

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Conditions:   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER2-positive Colorectal Cancer;   HER2-expressing Non-small Cell Lung Cancer
Interventions:   Drug: SBT6050;   Drug: trastuzumab deruxtecan;   Drug: tucatinib;   Drug: trastuzumab;   Drug: capecitabine
Sponsor:   Silverback Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Comments